Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Quadrise

    MCap

    GBP28m

    Last close

    GBP0.02

    ▲ 0.41 (26.62%)

    Substrate AI

    MCap

    EUR12m

    Last close

    EUR0.13

    ▲ 0.02 (18.18%)

    Games Workshop Group

    MCap

    GBP3,860m

    Last close

    GBP137.30

    ▲ 2,020.00 (17.25%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sareum Holdings – executive interview

Sareum Holdings – executive interview

Sareum Holdings — 3 videos in collection

More on this equity

Sareum Holdings (AIM: SAR) is a UK-listed drug-discovery company focused on the development of small molecule kinase inhibitors. Its in-house programmes are dual TYK2/JAK1 inhibitors: SDC-1801 for autoimmune diseases and SDC-1802 for cancer. The third development programme is SRA737, a CHK1 inhibitor targeting the DNA damage response network for the treatment of solid tumours. Sareum holds a 27.5% economic interest in SRA737.

In this video, we talk to Dr Stephen Parker, executive chairman at Sareum, about the potential to offer differentiation with SDC-1801’s dual inhibition approach, the recently presented positive Phase I data for the candidate, as well as next steps, which include plans for Phase II. We also discuss the company’s £3.4m equity raise, how the funds will be deployed to advance all pipeline assets through next stages of clinical development and key milestones for investors to watch out for.

< Previous

You may also be interested in these:

Healthcare

Sareum Holdings: Edison Open House Healthcare 2022

Healthcare

Sareum Holdings - Edison Open House interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free